Whitepaper: Unique solutions for drug discovery and development
Looking for solutions to resolve your unique challenges? We offer several customized products and services to move your discovery forward.
List view / Grid view
Looking for solutions to resolve your unique challenges? We offer several customized products and services to move your discovery forward.
Trinity researchers have discovered the secret to viral resistance, by screening women exposed to HCV.
A research team at the University of Exeter have found that the unexplored genomic control regions yield the key to finding causes of Congenital Hyperinsulinism.
Researchers show how monkeypox mutations cause virus to replicate, spread faster.
A new study found that as patients age, Huntington’s disease gradually impairs the important cellular housekeeping process autophagy, which is responsible for eliminating waste from cells.
UPF and John Hopkins scientists have discovered how cancer cells exposed to high viscosity environments change their movements to improve their invasiveness and favour metastases.
Scientists have generated polygenic risk scores for developing paediatric steroid sensitive nephrotic syndrome (pSSNS), a kidney disease in children.
Streamline your cancer research using this guide that groups antibodies against critical cancer biomarkers according to biomarker type or tissue type.
The researchers used a zebrafish model to test mutations in Mycn, a gene which causes Feingold syndrome.
The molecules, called SGDGs, may lead to new ways to treat age-related neurological diseases.
Researchers find monoclonal antibodies provided nearly complete protection against EBV infection and lymphoma when tested in mice.
Researchers have connected the loss of alpha-B insulin receptors in brain microvessels as contributors to insulin resistance and cognitive decline, with Alzheimer’s disease.
Scientists shed light on how genetic architecture in human retina cells determine gene expression, tissue-specific function, and disease phenotype in blinding diseases.
H84T-BanLec has viral-blocking abilities by binding to polysaccharides that are present on the surface of the viruses.
Dr Larysa Baraban, physicist at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) is researching a chip that should ultimately make it possible to develop personalised cancer immunotherapies.